RCA
IMRX icon

Resonant Capital Advisors’s Immuneering IMRX Stock Holding History

Resonant Capital Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$132K – 507
2025
Q4 		$132K Hold
20,000
– – 0.01% 438
2025
Q3 		$140K Buy
+20,000
New +$104K 0.01% 433

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Resonant Capital Advisors's IMRX Position: Q1 2026 in Review

Resonant Capital Advisors sold out of Immuneering (IMRX) in Q1 2026, closing a stake of 20,000 shares — an estimated $132K sold.

Resonant Capital Advisors first reported a position in IMRX in Q3 2025 and held it in 2 quarters. The position peaked at $140K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Resonant Capital Advisors reported no remaining Immuneering position as of Q1 2026 after selling out during the quarter.
  • Resonant Capital Advisors sold 20,000 Immuneering shares in Q1 2026, an estimated $132K.
  • Resonant Capital Advisors first reported a position in Immuneering in Q3 2025 and held it in 2 quarters.
  • Resonant Capital Advisors's Immuneering position peaked at $140K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Resonant Capital Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.